Myriad Genetics
MYGN
276 hedge funds and large institutions have $3.74B invested in Myriad Genetics in 2014 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 88 increasing their positions, 113 reducing their positions, and 37 closing their positions.
3% less funds holding
Funds holding: 284 → 276 (-8)
7% less capital invested
Capital invested by funds: $4.01B → $3.74B (-$271M)
16% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 37
22% less repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 113
26% less call options, than puts
Call options by funds: $43.8M | Put options by funds: $59.4M
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$88.1M |
| 2 |
D.E. Shaw & Co
New York
|
+$26.5M |
| 3 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$25.7M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
+$11M |
| 5 |
TCM
Tieton Capital Management
Yakima,
Washington
|
+$9.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$51.8M |
| 2 |
SCM
Sterling Capital Management
Charlotte,
North Carolina
|
-$40.5M |
| 3 |
NAP
New Amsterdam Partners
New York
|
-$29.5M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$26.4M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$20M |
MYGN Hedge Fund Activity: Q3 2014 in Review
276 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q3 2014, worth a combined $3.74B — down 6.8% from $4.01B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of MYGN and 31 opened new positions — a net loss of 6 holders — while 113 trimmed existing stakes and 88 added.
The largest buyer was Capital World Investors, adding an estimated $88.1M. The largest seller was Viking Global Investors, exiting entirely with an estimated $51.8M sold.
- 276 institutional investors held Myriad Genetics (MYGN) as of Q3 2014, down from 284 in Q2 2014.
- Funds reported $3.74B of Myriad Genetics stock for Q3 2014, down 6.8% quarter-over-quarter.
- 31 funds opened new Myriad Genetics positions in Q3 2014 and 37 closed out, a net change of -6 holders.
- The largest Myriad Genetics buyer in Q3 2014 was Capital World Investors, an estimated $88.1M added.
- The largest Myriad Genetics seller in Q3 2014 was Viking Global Investors, an estimated $51.8M sold.
Based on aggregated 13F filings for Q3 2014.